Here we show for the first time that there are major and progressive changes on the surface of vitreous collagen fibrils as a result of aging, and we believe this is the first study to analyze age-related surface changes on collagen fibrils from any tissue comprehensively. The collagen fibrils lost type IX collagen proteoglycan from their surface with aging and there was a concomitant increased surface exposure of type II collagen. We suggest that these changes predispose the fibrils to lateral fusion on contact, resulting in further liquefaction of the vitreous gel. However, the collagen fibrils of the vitreous are held in a semi-rigid network
6 so, despite an increased propensity to fusion with aging, in samples from aged subjects, individual fibrils were still observed that had not come into contact with other fibrils and fused. Additional factors such as eye movements may then contribute to the liquefaction process by bringing together collagen fibrils.
The age-related surface changes on the vitreous collagen fibrils may cause decreased vitreoretinal adhesion which, combined with the vitreous liquefaction, predisposes to PVD. The vitreous collagen fibrils at the vitreoretinal interface do not directly insert into the ILL, but are adherent to it while otherwise being oriented parallel to the ILL surface.
18 19 Therefore, it is likely that vitreoretinal adhesion is afforded by components on the surface of vitreous collagen fibrils linking (directly or indirectly) to the ILL and if the surfaces of the vitreous collagen fibrils are radically altered, vitreoretinal adhesion is consequently modified.
There was an exponential loss of cupromeronic blue labeled filaments with aging that is likely to reflect a loss of type IX collagen molecules (and their chondroitin sulfate side-chains) for the following reasons. Cupromeronic blue-labeled filaments are absent in chondroitin ABC lyase-treated vitreous
(Fig. 1) , demonstrating that the filaments contain chondroitin or dermatan sulfate. Vitreous contains two chondroitin sulfate proteoglycans, namely type IX collagen and versican,
16 but there is no evidence for the presence of dermatan sulfate.
16 20 To date, no small leucine-rich repeat chondroitin sulfate proteoglycans have been identified associated with vitreous collagen fibrils (these often decorate collagen fibrils in other tissues). Instead, vitreous collagen fibrils are decorated with a small leucine-rich repeat glycoprotein called opticin, which possesses sialylated O-linked oligosaccharides but no glycosaminoglycan chains.
21 22 The chondroitin sulfate chains on the vitreous collagen fibrils are likely to represent type IX collagen glycosaminoglycan side-chains (as opposed to versican) because they were often observed, like the type IX collagen core protein,
9 10 11 to be regularly aligned along the fibril surfaces in a
D-periodic distribution (whereas versican is linked to the hyaluronan network that fills the spaces between the vitreous collagen fibrils).
16 Finally, our results here show a strong correlation between the loss of chondroitin sulfate and the loss of immunogold labeling of type IX collagen core protein, with both having a half-life of 11 years, thus substantiating the argument that the filaments revealed by cupromeronic blue represent the glycosaminoglycan side-chains of type IX collagen. It is conceivable that instead of the chondroitin sulfate chains being lost from the fibril surface they are enzymatically desulfated, thus losing their ability to form crystallites with cupromeronic blue under the conditions of these experiments. However, this explanation is unlikely because of the clear correlation between the loss of the cupromeronic blue staining and the loss of type IX collagen immunogold labeling from the fibril surface.
The age-related loss of type IX collagen from the surface of vitreous fibrils is presumed to involve proteolysis as this collagen is covalently cross-linked into the fibrils.
12 The exponential fit to the graphs in
Figures 3A and 3B suggests that this proteolytic process occurs at a constant rate. The underlying mechanisms remain unclear but one possible explanation is that matrix metalloproteinase activity may play a role; MMP2 has been demonstrated in human vitreous humor
23 and this enzyme is capable of fragmenting type IX collagen and causing vitreous liquefaction.
24
In young adult bovine vitreous, type IX collagen content has been variously estimated to be between 7% and 25% of the collagen.
9 13 25 26 However, in adult human vitreous, type IX collagen content is likely to be much lower as it was virtually undetectable by Western blot analysis of pepsin-derived extracts. Cartilage collagen fibrils also contain collagen types II, IX, and V/XI, and, similarly, in mature human cartilage, type IX collagen is at low levels, representing only 1–2% of the total collagen.
12 Mature cartilage contains thin collagen fibrils that resemble vitreous collagen fibrils and thick fibrils that probably represent aggregates of these thin fibrils.
27 Interestingly, only the thin fibrils are coated with type IX collagen, so a similar process may be occurring in vitreous and cartilage whereby the thin fibrils aggregate with increasing age because of surface changes including the loss of type IX collagen.
27
The age-related loss of type IX collagen and the concomitant increase in surface exposure of type II collagen could modulate other vitreoretinal disease processes. Cells proliferate within the vitreous cavity in conditions such as proliferative diabetic retinopathy and proliferative vitreoretinopathy, and the ability of cells to interact with vitreous collagen (e.g., through integrins) is likely to be influenced by the surface composition of the fibrils. Furthermore, the vitreous humor provides an important reservoir of growth factors within the eye, and it is likely that some of these are retained by binding vitreous collagen fibrils. Therefore, growth factor content and availability could change with aging owing to altered interactions with vitreous collagen.
The authors thank the staff of Manchester Royal Eye Hospital Eye Bank for providing eye tissue, Maryline Fresquet for technical support, and David Henson (University of Manchester) for assistance with data analysis.